23andMe IPO

23andMe pioneered the direct-to-consumer genetic testing market, offering individuals insights into their ancestry, health predispositions, and genetic traits through saliva-based DNA analysis. The company has built one of the world's largest genetic databases, with over 12 million customers providing genetic information that serves as the foundation for both their consumer products and their pharmaceutical research initiatives. Their health reports cover genetic predispositions for various conditions, carrier status for inherited diseases, and pharmacogenomics insights for drug response.

Beyond consumer testing, 23andMe has evolved into a drug discovery company, leveraging their massive genetic dataset to identify novel therapeutic targets and develop treatments for various diseases. Their research collaborations with pharmaceutical companies and their internal drug development programs represent a significant pivot toward becoming a biotechnology company that uses consumer genetics as a data acquisition strategy. However, the company has faced challenges including regulatory scrutiny, privacy concerns, and increased competition, while working to demonstrate the commercial viability of their research-driven business model in the pharmaceutical sector.